| Literature DB >> 21912579 |
Wirginia Krzyściak1, Agnieszka Cierniak, Mariusz Kózka, Joanna Kozieł.
Abstract
The main goal of the work reported here was to determine the degree of oxidative/alkali-labile DNA damages in peripheral blood as well as in the blood stasis from varicose vein of (chronic venous disorder) CVD patients. Moreover, determination of the impact of Detralex usage on the level of (oxidative) DNA damages in CVD patients was evaluated as well.The degree of oxidative DNA damages was studied in a group consisted of thirty patients with diagnosed chronic venous insufficiency (CVI) in the 2nd and 3rd degree, according to clinical state, etiology, anatomy and pathophysiology (CEAP), and qualified to surgical procedure. The control group consisted of normal volunteers (blood donors) qualified during standard examinations at Regional Centers of Blood Donation and Blood Therapy.The comet assay was used for determination of DNA damages.Analyses of the obtained results showed increase in the level of oxidative/alkali-labile DNA damages in lymphocytes originating from antebrachial blood of CVD patients as compared to the control group (Control) (p < 0.002; ANOVA). In addition, it was demonstrated that the usage of Detralex® resulted in decrease of the level of oxidative/alkali-labile DNA damages in CVD patients as compared to patients without Detralex® treatment (p < 0.001; ANOVA).Based on findings from the study, it may be hypothesized about occurrence of significant oxidative DNA damages as the consequence of strong oxidative stress in CVD. In addition, antioxidative effectiveness of Detralexu® was observed at the recommended dose, one tablet twice daily.Entities:
Keywords: Reactive oxygen species (ROS); chronic venous insufficiency (CVI); micronized purified flavonoid fraction (MPFF).
Year: 2011 PMID: 21912579 PMCID: PMC3162189 DOI: 10.2174/1874192401105010179
Source DB: PubMed Journal: Open Cardiovasc Med J ISSN: 1874-1924
Diseases where Increased Level of Oxidative DNA Damages was Observed
| Disease | Dna Damage | Comment |
|---|---|---|
| Acute Lymphoblastic leukemia | FapyGua, 8-OH-Gua, | Significant increase in DNA damage level in ALL in comparison to control ( |
| 8-OH-dG | Significant increase in 8-OH-dG level ( | |
| Alzheimer's disease | 8-OH-dG | Higher 8-0H-dG level in cortex and cerebellum [ |
| Amyotrophic lateral sclerosis | 8-OH-dG | Significant increase in 8-OH-dG level in comparison to control [ |
| Primary breast cancer | 8-OH-dG (DNA) | Increased 8-OH-dG level ( |
| Cardiovascular diseases | 8-OH-dG (DNA) | Increased 8-OH-dG level in lymphocytes ( |
| Colorectal carcinoma | 8-OH-dG (DNA) | Significant increase in 8-OH-dG level in carcinoma tissue in comparison to normal mucous membrane [ |
| Gynecological neoplasms | 8-OH-dG (urine) | Significant increase in 8-OH-dG level ( |
| Cervical carcinoma | 8-OH-dG (DNA) | Significant increase in 8-OH-dG level in comparison to control [ |
| Renal cell carcinoma | 8-OH-dG (DNA) | Significant increase in 8-OH level ( |
| Chronic liver disease | 8-OH-dG (DNA) | Significant increase in 8-OH-dG level ( |
| HCV | 8-OH-dG (DNA) | Significant increase in 8-OH-dG level ( |
| Cystic fibrosis | 8-OH-dG (urine) | Increased level of 8-OH-dG in comparison to control [ |
| Small cell lung carcinoma | 8-OH-dG (urine) | Increase in 8-OH-dG level in comparison to control ( |
| Pulmonary carcinoma | 8-OH-dG (DNA) | Increase in 8-OH-dG level in lymphocytes and carcinoma tissues [ |
| Atopic dermatitis | 8-OH-dG (urine) | Increase in 8-OH-dG level ( |
| Gastric adenoma | 8-OH-dG (DNA) | Significant increase in 8-OH-dG level in cancer tissues in comparison to normal tissues [ |
| Type I and II diabetes | 8-OH-dG (urine) | Level of 8-OH-dG in patients with type I and II diabetes significantly increased in comparison to control [ |
| Down syndrome | 8-OH-dG (urine) | Increase of 8-OH-dG level in patients in comparison to control [ |
| Rheumatoid arthritis | 8-OH-dG (urine) | Increase of 8-OH-dG level ( |
| Chronic venous disease | 8-OH-dG (DNA) | Increase of 8-OH-dG level ( |